Seven oral presentations will unveil novel immunotherapy insights, including IBI363, at one of oncology’s biggest global ...

"The two NDAs approval of DOVBLERON is a reflection of its potential best-in-class efficacy to fulfill the urgent need of patients with ROS1-positive NSCLC," said Hui Zhou, Innovent's Senior Vice ...